GlassScriptPhysician profile
Joseph L Martinez
NPI 1528398203
$9,935.60
in general payments reported to CMS, 2019-2025
13 companies · $2,014 in 2025
The $2,014 reported for 2025 was more than what a typical Neurological Surgery provider received nationally (typical 2025 total: $604).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,844 · 2020: $487 · 2021: $1,675 · 2022: $639 · 2023: $880 · 2024: $396 · 2025: $2,014.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,888 · Travel and Lodging: $1,403.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,887.71 |
| Travel and Lodging | $1,402.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Spineart USA INC | $5,211.10 | 2019-2023 | Perla Tl |
| Spineology INC. | $1,900.50 | 2025 | |
| Stryker Corporation | $1,577.72 | 2019-2024 | Na |
| Medtronic, INC. | $446.53 | 2022-2024 | Intellis Adaptivestim, Mazor X System, Anteralign Spinal System With Titan Nanolock Surface Technology |
| Depuy Synthes Sales INC. | $306.03 | 2021-2025 | Viper, Matrixneuro |
| Boston Scientific Corporation | $191.32 | 2020-2021 | |
| Spinal Elements, INC. | $95.69 | 2024 | |
| Flowonix Medical Incorporated | $61.74 | 2019 | |
| Vertiflex, INC. | $52.39 | 2019 | |
| Cerapedics INC. | $32.77 | 2023 | I-Factor Peptide Enhanced Bone Graft |
| Nuvasive, INC. | $21.24 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $19.87 | 2020 | |
| Neurocrine Biosciences, INC. | $18.70 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Martinez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.